Pay in 4 interest-free payments of $5.34 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Xtandi (enzalutamide) Disease area(s): Oncology Manufacturer(s): Astellas/Pfizer 2024 Sales (USD): $7.94 billion Why it sold so well: In 2024, Astellas Pharmas Xtandi, co-marketed with Pfizer, posted strong sales growth, with revenues reaching 703.1 billion ($4.64 billion) for the first nine months (April 1, 2024 to December 31, 2024), marking a 25.6% increase compared to the same period in the previous year
Cardiac Catheterization Policy number: M.33 Summary: Covers right, left, or combined heart catheterization when clinically indicated for diagnosis or treatment planning of cardiac conditions, while excluding non-indicated uses such as routine angioplasty or electrophysiologic studies
To explore your options and take the next step in your journey
In the context of sepsis, experimental studies have demonstrated that adiponectin deficiency exacerbates inflammation, promotes leukocytes and platelet adhesion, and compromises bloodbrain barrier integrity, partly through the upregulation of E-selectin
Therapeutic scope and regulatory status Afamelanotide is approved for EPP to reduce phototoxicity
For patients on a weight-loss plan or low-carb diet, injections help maximize fat utilization during workouts and daily activity
US$ 23.52
US$ 21.68
US$ 21.60
US$ 24.81
US$ 21.76
US$ 21.99
